December 28, 2020 09:33 AM ESTUpdated December 30, 10:03 AM
News Briefing

News brief­ing: In­cyte bankrolls an ear­ly-stage myelofi­bro­sis pair-up with Jakafi; In­no­Care gets Chi­nese ap­proval for lead drug

Max Gelman

Senior Editor

Look­ing to fur­ther bol­ster its block­buster fran­chise for Jakafi, In­cyte has struck a deal to part­ner up on a new com­bi­na­tion ap­proach to treat­ing myelofi­bro­sis …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

ADC biotech Ad­cen­do nabs $135M Se­ries B as it en­ters the clin­ic

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times